ReviewTherapeutic advances in drug safety2025
Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration.
Review in Therapeutic advances in drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Adverse Drug Reactions: Building Drug Safety Beyond Marketing Authorisation.Journal of clinical medicine · 2026Article
- Intelligent Automation Improved Efficiency in Pharmacovigilance Safety Signal Assessment.Clinical pharmacology and therapeutics · 2026Article
- Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment Framework.Drug safety · 2026Review
- A parallel dual-stream state-space module for reliable and efficient biomedical relation extraction.PLoS computational biology · 2026Article
- Innovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative models.Journal of thrombosis and thrombolysis · 2026Review
- Artificial Intelligence in Drug Discovery and Development: Raising Quality per Decision.Pharmacopsychiatry · 2026Review
- Article
- Artificial intelligence in pharmacovigilance: toward real-time, explainable, and global drug-safety systems.Annals of medicine and surgery (2012) · 2026Article
- Closing the loop: human-augmented, mechanistically enhanced AI for proactive management of drug-drug interactions.Frontiers in pharmacology · 2026Article
- How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026Article
- Cross national pharmacovigilance analysis of drug-induced delirium: a comparative study using the US FAERS, Japanese JADER, and canadian CVAR datasets.Frontiers in pharmacology · 2026Article
- A lightweight hybrid deep learning framework for multi-pill detection, multi-attribute recognition, OCR-based imprint analysis, and metadata retrieval.Frontiers in artificial intelligence · 2026Article
- The promises and perils of artificial intelligence in clinical medicine: a dual perspective from internal medicine and pediatrics.Croatian medical journal · 2025Article
- Real-world pharmacovigilance for anti-Aβ therapies using a large language model.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) has rapidly evolved from experimental applications in pharmacovigilance (PV) to being considered for routine use. This review critically examines AI's potential to revolutionize drug safety monitoring, focusing on practical implementation challenges such as ensuring AI's consistent and transparent performance, reducing multiple sources of bias, and addressing interpretability issues. It emphasizes the transition from experimental use to a routine, scalable capability within PV. It examines AI's evidence base in specific applications, its ability to enhance actionable insights, and how organizations can safeguard against unintended consequences in multi-AI system environments. These considerations are vital as AI moves from theory to practice in PV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.